Dopamine D2 receptor SPECT in corticobasal syndrome and autopsy-confirmed corticobasal degeneration

Parkinsonism and Related Disorders

Volumn 19, Issue 2, 2013, Pages 222-226

  Pirker, Susanne ^a,b   Perju Dumbrava, Laura ^c   Kovacs, Gabor G ^c   Traub Weidinger, Tatiana ^b   Asenbaum, Susanne ^b   Pirker, Walter ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atypical parkinsonism; Corticobasal degeneration; Corticobasal syndrome; Dopamine D2 receptors; Single photon emission computerized tomography

Indexed keywords

DOPAMINE 2 RECEPTOR; IOLOPRIDE I 123;

ADULT; AGED; ARTICLE; AUTOPSY; BOLUS INJECTION; BRAIN DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; CORTICOBASAL SYNDROME; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; AUTOPSY; BASAL GANGLIA DISEASES; BENZAMIDES; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PYRROLIDINES; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; RETROSPECTIVE STUDIES; SYNDROME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84873709809     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.10.010     Document Type: Article

References (22)

1. Brücke T., Podreka I., Angelberger P., Wenger S., Topitz A., Küfferle B., et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991, 11:220-228.
2. Tatsch K., Schwarz J., Oertel W.H., Kirsch C.M. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun 1991, 12:699-707.
3. Schwarz J., Tatsch K., Gasser T., Arnold G., Pogarell O., Künig G., et al. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord 1992, 13:16-19.
4. van Royen E., Verhoeff N.F., Speelman J.D., Wolters E.C., Kuiper M.A., Janssen A.G. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity activity demonstrated by 123I-IBZM single photon emission computed tomography. Arch Neurol 1993, 50:513-516.
5. Boeve B.F. The multiple phenotypes of corticobasal syndrome and corticobasal degeneration: implications for further study. J Mol Neurosci 2011, 45:350-353.
6. Grimes D.A., Lang A.E., Bergeron C.B. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999, 53:1969-1974.
7. Hughes A.J., Daniel S.E., Ben-Shlomo Y., Lees A.J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002, 125:861-870.
8. Boeve B.F. Corticobasal degeneration: the syndrome and the disease. Atypical parkinsonian disorders: clinical and research aspects 2005, 309-334. Humana Press, Totawa, NJ. I. Litvan (Ed.).
9. Murray R., Neumann M., Forman M.S., Farmer J., Massimo L., Rice A., et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 2007, 68:1274-1283.
10. Ling H., O'Sullivan S.S., Holton J.L., Revesz T., Massey L.A., Williams D.R., et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010, 133:2045-2057.
11. Dickson D.W., Bergeron C., Chin S.S., Duyckaerts C., Horoupian D., Ikeda K., et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002, 61:935-946.
12. Klaffke S., Kuhn A.A., Plotkin M., Amthauer H., Harnack D., Felix R., et al. Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord 2006, 21:1724-1727.
13. Frisoni G.B., Pizzolato G., Zanetti O., Bianchetti A., Chierichetti F., Trabucchi M. Corticobasal degeneration: neuropsychological assessment and dopamine D2 receptor SPECT analysis. Eur Neurol 1995, 35:50-54.
14. Plotkin M., Amthauer H., Klaffke S., Kühn A., Lüdemann L., Arnold G., et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 2005, 112:677-692.
15. Boeve B.F., Lang A.E., Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003, 54:S15-S19.
16. Tauscher J., Küfferle B., Asenbaum S., Tauscher-Wisniewski S., Kasper S. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology 2002, 162:42-49.
17. Lee S.E., Rabinovici G.D., Mayo M.C., Wilson S.M., Seeley W.W., DeArmond S.J., et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011, 70:327-340.
18. Kovacs G.G., Budka H. Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. Clin Neuropathol 2010, 29:271-288.
19. Gibb W.R., Luthert P.J., Marsden C.D. Corticobasal degeneration. Brain 1989, 112:1171-1192.
20. Mori H., Nishimura M., Namba Y., Oda M. Corticobasal degeneration: a disease with widespread appearance of abnormal tau and neurofibrillary tangles, and its relation to progressive supranuclear palsy. Acta Neuropathol 1994, 88:113-121.
21. Rinne J.O., Lee M.S., Thompson P.D., Marsden C.D. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994, 117:1183-1196.
22. Boeve B.F., Maraganore D.M., Parisi J.E., Ahlskog J.E., Graff-Radford N., Caselli R.J., et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999, 53:795-800.